WuXi AppTec Co., Ltd. Class A
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ge Li
- Full Time Employees
- 33,834
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 288 Fute Zhong Road Shanghai SH China 200131
- IPO Date
- May 8, 2018
- Website
- wuxiapptec.com.cn
- Similar Companies
- Business
- WuXi AppTec Co., Ltd. (603259.SS) is a leading global contract research, development, and manufacturing organization (CRDMO) that provides integrated end-to-end R&D and manufacturing services to the pharmaceutical, biotechnology, and life sciences industries; its core offerings span WuXi Chemistry for small molecule drug discovery, process development, and API manufacturing; WuXi Biology for target identification, hit-to-lead optimization, and candidate selection across small molecules, biologics, peptides, and oligonucleotides; WuXi Testing for preclinical safety assessments, bioanalysis, DMPK studies, and formulation development; and advanced solutions including Laboratory Testing Division services for drug and medical device testing from preclinical to clinical stages. Founded in 2000 and headquartered in Shanghai, China, the company operates approximately 20 research and manufacturing sites across Asia, Europe, and North America, including major hubs in the United States, Germany, Switzerland, and Singapore, serving nearly 6,000 customers from over 30 countries such as GlaxoSmithKline, AstraZeneca, Pfizer, and Jiangsu Hengrui with around 39,000 employees as of 2025. In recent developments, WuXi AppTec signed a definitive agreement in December 2024 to sell its U.S. and U.K.-based WuXi Advanced Therapies (cell and gene therapy CTDMO) unit to Altaris, LLC, with the transaction expected to close in the first half of 2025; divested its U.S. medical device testing operations in Minnesota and Georgia to NAMSA in January 2025; and reached a definitive agreement in October 2025 with Hillhouse Investment Management to sell its China-based clinical research services, including WuXi Clinical (CRO) and WuXi MedKey (SMO), to sharpen focus on its core CRDMO platform comprising WuXi Chemistry, Biology, and Testing; additionally, its Changzhou and Taixing API sites passed FDA inspections without observations in March 2025, and it completed a second RMB1.0 billion A-share repurchase program in August 2025.
Company News
WuXi AppTec (OTCMKTS:WUXAY) Sees Unusually-High Trading Volume – Time to Buy?
WuXi AppTec Earns EcoVadis Gold Medal for Third Consecutive Year, Ranking Among Global Top 5% for Sustainability
Recent Price Trend in Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) is Your Friend, Here's Why
WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion
Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) Is a Great Choice for 'Trend' Investors, Here's Why
Contrasting Sotera Health (NASDAQ:SHC) & WuXi AppTec (OTCMKTS:WUXIF)
Here's Why Momentum in Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) Should Keep going
WuXi AppTec files complaint against U.S. DoD for linking it to Chinese military
WuXi AppTec Recognized as a Top-Performing Company on 2026 Dow Jones Best-in-Class World Index
Short Interest in WuXi AppTec Co., Ltd. (OTCMKTS:WUXAY) Increases By 76.7%
WuXi AppTec Co., Ltd. (WUXAY) Q4 2025 Earnings Call Transcript
WuXi AppTec Co., Ltd. (OTCMKTS:WUXAY) Short Interest Update
WuXi AppTec Co., Ltd. (WUXAY) Presents at 44th Annual J.P.
WuXi AppTec (OTCMKTS:WUXIF) Shares Up 1.6% – Time to Buy?
WuXi AppTec (OTCMKTS:WUXAY) Shares Down 1.4% – What’s Next?
WuXi AppTec Receives Frost & Sullivan's 2025 Global Company of the Year Award in the CRDMO Industry
China's Corporate Pivots: Alibaba's Food Delivery Gambit and WuXi AppTec's Geopolitical Hedge
WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends
WuXi AppTec Completes Second RMB1.0 Billion A-Share Repurchase Program in 2025, All Repurchased Shares to Be Cancelled
WuXi AppTec Named Constituent of the FTSE4Good Index Series for Third Consecutive Year